ChemoTech have developed a new patented treatment technology platform called TSE – Tumour Specific Electroporation™
TSE is a groundbreaking advancement in cancer treatment, developed following an in-depth evaluation of many ablative and destructive oncology therapies including the older static electroporation. Leveraging robust clinical evidence supporting electroporation’s efficacy in treating malignant tumours, ChemoTech has pioneered the first dynamic electroporation technology. This innovation helps the treating physician avoid high and destructive currents, offering a safer and more precise treatment with limited damage to healthy tissue. Protected by multiple patents, TSE represents a unique and in some ways revolutionary approach in oncology using a patented CE-marked system for treating tumours.
Furthermore, our quality management system is certified according to ISO 13485:2016 Medical devices – Quality management systems – Requirements for regulatory purposes.
Adapting and calibrating the technology, to be powerful enough to treat the tumour without generating destruction and ablation of healthy tissue is central to the TSE technology.
TSE is designed to minimize the severe necrosis typically caused by traditional ablation and static electroporation methods. Instead of inducing rapid tissue breakdowns, TSE promotes apoptosis (programmed cell death), while sparing healthy surrounding tissue. This approach has been successfully used to treat hundreds of patients with cancers of the skin, head and neck, breast, bone, and pancreas, including cases unresponsive to standard therapies.
TSE’s effectiveness lies in its patented innovation that adapts the electric field to the specific characteristics of each tumour. Excessively strong fields, which can cause ablation and necrosis by permanently destroying the cell’s membrane, including cells in healthy tissue, are avoided. Instead, TSE is designed to optimize the reversible electroporation (mode of action), allowing cancer drugs to penetrate tumour cells effectively and establish the wanted apoptosis by breaking down the DNA before the cells can be diverted into new cells. This precision minimizes damage to healthy tissue while maximizing therapeutic outcomes.
In the case of an excessively strong electric field, heat ablation occurs, which means that even healthy tissue dies (necrotic destruction). Slightly lower strength (orange in the graph) also leads to necrotic destruction, which can be used for smaller tumours. Reversible electroporation – green – in in the graph is the goal of the treatment).
In 2016, a case series involving 23 patients treated with IQwave™ demonstrated the safety, efficacy, and future potential of TSE. The study included patients with breast cancer, head and neck cancer, and rare sarcomas, all of whom responded favourably. Unlike earlier technologies, TSE provides even distribution of the electrical field, minimizing necrosis and avoiding damage to healthy tissue while promoting apoptotic tumour cell death and immune modulation.
An investigator-initiated clinical study is ongoing at the All India Institute of Medical Sciences (AIIMS) in Jodhpur, India, to further evaluate the immunological mechanisms of cell death due to TSE in head- and neck cancer. Apart from including efficacy endpoints (according to state-of-the-art RECIST 1.1), the study will provide insights into possible TSE-based combinatorial approaches to the treatment of solid cancers.
A clinical case series for pancreatic cancer is also ongoing at Ulis Medical Centre (Ulis MC) in Zaporizhia, Ukraine, with promising clinical outcomes in preliminary assessments.
Kalavathy Gurusamy et al. Trends in Cancer Research Vol 13, 2018:29-41,
Esienhauer New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, 45,2009, 228-247
ChemoTech’s patented technology enables multidimensional electroporation, allowing electrodes to be inserted at various angles to reach tumours up to 15 cm deep. This flexibility reduces the risk of overtreatment or undertreatment and avoids critical structures such as blood vessels and bones. This innovation paves the way for new indications, including stereotactic treatments and minimally invasive procedures for deeper tumours.
ChemoTech remains committed to advancing TSE through continued R&D efforts, for both curative and later palliative stages of treatments. Our extended target for TSE includes addressing the more deep-seated tumours, such as pancreatic, liver and prostate cancer, with minimally invasive techniques such as laparoscopic or robotic approaches.
ChemoTech actively collaborates with oncologists, researchers, and medical institutions worldwide to refine and expand TSE’s applications. Partnerships with leading cancer centres in India and other regions support early proof-of-concept studies and accelerate clinical adoption.
ChemoTech’s Animal Care business area offers a versatile platform for advancing and refining our innovative products and treatments.
The IQwave™ system is manufactured to the highest quality standards, ensuring reliability and accessibility for healthcare providers globally. ChemoTech’s distribution networks are designed to bring TSE to patients and practitioners worldwide, solidifying its role as a leader in innovative cancer therapies.
(Dynamic-ElectroEnhanced Pain Control™)
Scandinavian ChemoTech AB has a short, animated video that explains its next R&D project D-EEPC (Dynamic-ElectroEnhanced Pain Control™). This project can potentially become a revolutionary treatment for treating pain for patients with secondary bone cancer, especially located in the spine.
Phase 1 –
Cytostatic administration
When using electroporation to enhance the effects of cytostatic the therapy begins by administering cytotoxic drugs to the patient.
Cytostatic, such as Bleomycin, are inefficient outside the tumour cells, which is why the full effect of the cytostatic drug can only be achieved when combined with electroporation.
Phase 2 –
Treatment with TSE
By treating the tumour cell with TSE the cell membrane becomes reversibly permeable (formation of small pores and the ability to pass through substances), which allows the cytostatic to penetrate the cell nucleus.
By increasing the permeability, considerably lower doses of cytostatic are required to achieve a therapeutic effect. The low dose of cytostatic significantly lowers the risk of side effects.
Phase 3 – Cytostatic enclosed in the tumour cell
After each treatment cycle with TSE, the cells reverse to a none-permeable state. This means that the cytostatic molecules become trapped inside the tumour cell.
Phase 4 – Cell death and immunological effect
The three significant effects of this therapy are:
Get in touch
Are you interested in our products?
Our team is here to help with any questions about our products, patents or anything else you may need help with.
This website uses cookies. If you continue to browse the website, you agree to the use of cookies.